.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Harvard Business School
Healthtrust
Merck
US Department of Justice
Cantor Fitzgerald
Novartis
Fuji
Mallinckrodt
Daiichi Sankyo

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Sustained release formulations of water soluble peptides
Abstract:The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.
Inventor(s): Bodmer; David (Klingnau, CH), Fong; Jones W. (Parsippany, NJ), Kissel; Thomas (Staufen, DE), Maulding; Hawkins V. (Mendham, NJ), Nagele; Oskar (Sissach, CH), Pearson; Jane E. (Ogdensburg, NJ)
Assignee: Novartis AG (Summit, NJ)
Filing Date:Jun 06, 1995
Application Number:08/470,907
Claims:1. A process for the production of microparticles comprising ostreotide distributed throughout, which comprises intensively mixing:

a) a solution of octreotide in a weight/volume ratio of 2.5 g/10 ml in a buffer of pH 3-8 and

b) a solution of a polylactide-co-glycolide in methylene chloride in a weight/volume ratio of 40 g/100 ml in such a manner that the weight/weight ratio of the drug to the polymer is 1/16 and the volume/volume ratio of the aqueous medium/organic solvent is 1/10, intensively mixing the w/o-emulsion of a) in b) together with

c) an excess of a buffer of a pH 3-8, containing gelatine in a concentration of 0.5% of weight at a volume/volume mixing speed ratio of ab)/c) of 1/40, without adding any drug retaining substance to the water-in-oil emulsion or applying any intermediate viscosity increasing step, hardening the embryonic microparticles in the formed w/o/w-emulsion by evaporation of the methylene chloride and by isolating, washing and drying the generated microparticles.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Accenture
Covington
McKesson
Daiichi Sankyo
UBS
Julphar
US Army
McKinsey
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot